Kamada Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Kamada Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel Kamada Ltd.January 13, 2021 GMT The Three Products Are Expected to Be Launched, Subject to Israeli Ministry of Health Approval, Between 2022 and 2024 Potential Collective Maximum Sales of the Three Products in the Israeli Market is Estimated at $5-$7 Million Annually These Sales Are i n Addition to the Potential $20-$30 Million from the Recently Licensed Alvotech Biosimilar Portfolio REHOVOT, Israel, Ja...
Source: apnews.com